Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infliximab therapy in hematologic malignancies: handle with care.
Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F. Stagno F, et al. Among authors: vitale sr. Haematologica. 2012 Aug;97(8):e26; author reply e27. doi: 10.3324/haematol.2012.067934. Haematologica. 2012. PMID: 22855845 Free PMC article. No abstract available.
Diagnosis of blastic phase of chronic myeloid leukemia.
Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F. Stagno F, et al. Among authors: vitale sr. Acta Haematol. 2012;127(4):198. doi: 10.1159/000337267. Epub 2012 Mar 21. Acta Haematol. 2012. PMID: 22441204 No abstract available.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F. Stella S, et al. Among authors: vitale sr. Int J Mol Sci. 2019 May 6;20(9):2226. doi: 10.3390/ijms20092226. Int J Mol Sci. 2019. PMID: 31064152 Free PMC article.
Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.
Manzella L, Massimino M, Stella S, Tirrò E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C, Di Gregorio S, Russo M, Malandrino P, Vigneri P. Manzella L, et al. Among authors: vitale sr. Int J Mol Sci. 2019 Jul 2;20(13):3258. doi: 10.3390/ijms20133258. Int J Mol Sci. 2019. PMID: 31269742 Free PMC article. Review.
Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.
Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, Di Raimondo F, Manzella L. Massimino M, et al. Among authors: vitale sr. Oncol Lett. 2019 Sep;18(3):2648-2653. doi: 10.3892/ol.2019.10558. Epub 2019 Jul 4. Oncol Lett. 2019. PMID: 31404304 Free PMC article.
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.
Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P. Pennisi MS, et al. Among authors: vitale sr. Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019. Front Oncol. 2019. PMID: 31456947 Free PMC article.
47 results